Hepatitis B virus (HBV) can cause chronic hepatitis B, which may lead to cirrhosis and liver cancer. Type I interferon (IFN) is an approved drug for the treatment of chronic hepatitis B. However, the fundamental mechanisms of antiviral action by type I IFN and the downstream signaling pathway are unclear. TRIM25 is an IFN-stimulated gene (ISG) that has an important role in RIG-I ubiquitination and activation. Whether TRIM25 is induced in liver cells by type I IFN to mediate anti-HBV function remains unclear. Here we report that interleukin-27 (IL-27) has a critical role in IFN-induced TRIM25 upregulation. TRIM25 induction requires both STAT1 and STAT3. In TRIM25 knockout HepG2 cells, type I IFN production was consistently attenuated and HBV replication was increased, whereas overexpression of TRIM25 in HepG2 cells resulted in elevated IFN production and reduced HBV replication. More interestingly, we found that TRIM25 expression was downregulated in HBV patients and the addition of serum samples from HBV patients could inhibit TRIM25 expression in HepG2 cells, suggesting that HBV might have involved a mechanism to inhibit antiviral ISG expression and induce IFN resistance. Collectively, our results demonstrate that type I IFN -induced TRIM25 is an important factor in inhibiting HBV replication, and the IFN-IL-27-TRIM25 axis may represent a new target for treating HBV infection.
INTRODUCTION
Despite severe side effects, type I interferon (IFN) treatment remains an antiviral option for treating chronic hepatitis B. Type I IFNs (IFN-α, IFN-β, IFN-ε and others) have been recognized as the major antiviral cytokine in vertebrates, 1 constituting one of the most important innate immune responses to viral infection including hepatitis B virus (HBV) and hepatitis C virus infection. The antiviral function of type I IFN is carried out through its binding to the type I IFN receptor (IFNΑR1, 2), the activation of the JAK/STAT pathway and the subsequent induction of a large number of IFN-stimulated genes (ISGs), 2 which can inhibit different stages of the viral life cycle including entry, replication, assembly and budding. 3, 4 However, due to co-evolution, many viruses have acquired the ability to counter the antiviral response induced by type I IFN. A thorough understanding of the interactions between host cells and HBV will improve antiviral treatment.
Classically, type I IFN stimulation leads to the formation and activation of the STAT1/2 heterodimer, and the dimer finally moves into the nucleus and binds to IFN-stimulated response elements (ISREs) together with IRF9. In addition, STAT homodimers or heterodimers formed from different combinations of STAT1, 3, 4, 5 or 6 during IFN signaling can also have roles in binding to ISREs or IFN-activated site, which could further induce ISG production. 5, 6 In a sequential response, IFN induced IL-27 and then activated STAT3. 7 Another report showed that in Doudi cells, which are sensitive to IFN treatment, the induction of CXCL11 by IFN depends on recruiting the transcriptional activators p65 and IRF1 through STAT3. 8 These studies suggested that STAT3 may be involved in regulating the production of certain ISGs. It is not clear whether STAT3 is required to regulate ISGs production during HBV infection.
IL-27 is primarily produced by innate immune cells and can suppress T-cell immunity, including the inhibition of Th17 and Th1 differentiation in several infection models. [9] [10] [11] Another function of IL-27 is to regulate transcription activity. For example, IFN-induced IL-27 secretion was responsible for both STAT1 and STAT3 activation. 7, 12 In hepatic cells, IL-27 was reported to modulate CXCL9, CXCL10 and CXCL11 chemokines. 13 The biological function of IL-27 in regulating ISGs induction in HBV infection is largely unknown.
The tripartite motif family (TRIM) is a protein family and is known for ring-finger E3 ubiquitin ligase activity. All family members of TRIM proteins comprise a RING domain, one or two B-box domains and an associated coiled-coil domain in the amino-terminal region. [14] [15] [16] Many TRIM members are IFN -inducible genes and are important for restricting viral infection. [17] [18] [19] As an important member of the TRIM family, TRIM25 was previously shown to inhibit HBV replication 20 ; however, the mechanisms remain undefined. TRIM25 has been suggested to promote IFN-β production by activating the RIG-I signaling pathway in mouse embryonic fibroblast (MEF) cells. 21 In this study, we investigated the interplays between TRIM25 and IFN signaling during HBV infection. We found that enforced expression of TRIM25 in HepG2 cells induces type I IFN expression, which could further suppress HBV replication. Interestingly, TRIM25 expression was attenuated in the peripheral blood mononuclear cells (PBMCs) of HBV patients; in addition, HBV-positive serum also downregulated TRIM25 expression in HepG2 cells. These findings may explain the resistance to IFN treatment observed in some HBV patients. IFN-TRIM25 regulatory circuitry may warrant exploration in optimizing IFN treatment.
MATERIALS AND METHODS
Cell culture, plasmids and reagents Human embryonic kidney cell line HEK293T, HepG2.2.15 and HepG2 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% inactivated fetal bovine serum, penicillin (100 IU/ml) and streptomycin (100 mg/ml) at 37°C with 5% CO 2 . For mice bone-marrow-derived macrophage (BMM) differentiation, bone marrow cells were collected from wild-type IL27R1 −/− mice and differentiated in DMEM supplemented with 10% fetal bovine serum, 1% penicillin/ streptomycin and 10 ng/ml of M-CSF for 7 days. The IL27R1 −/− mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA), stock no: 018078. Antibodies against tubulin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies against p-STAT3 (705), STAT3, STAT1 and TRIM25 were supplied by Cell Signaling Technology (Danvers, MA, USA). Antibody against GAPDH was obtained from Proteintech (Wuhan, Hubei, China). Human IL27 recombinant protein was supplied by eBioscience (San Diego, CA, USA) and IL-27-neutralizing antibody was from R&D SYSTEMS (Minneapolis, MN, USA). polydAdT and polyIC were purchased from Invivogen (San Diego, CA, USA). The expression construct of TRIM25 was generated by cloning the coding region sequence of human TRIM25 into VR1012 expression vector, the pHBV1.3 plasmids was kindly supplied by Dr Lishan Su in University of North Carolina.
RNA extraction and quantitative real-time PCR (Q-PCR)
Total RNA was extracted from cells using an EasyPure RNA kit (TransGen, Beijing, China) and then converted to first-strand cDNA using TransScript First-Strand cDNA Synthesis SuperMix (TransGen). HBV DNA was isolated from cells according to the kit instructions (TransGen). Housekeeping gene GAPDH was used as an internal control for quantitation, and gene expression was quantified as previously described. 22 The sequences of gene-specific primers used for Q-PCR are shown in Supplementary Table S1 .
Immunoblotting
Immunoblotting was conducted as previously described. 23 In brief, the whole cell was lysed by adding lysis buffer (20 mM HEPES, 350 mM NaCl, 20% glycerol, 1% NP40, 1 mM MgCl 2 , 0.5 mM EDTA, 0.1 mM EGTA and 0.5 mM dithiothreitol) together with protease inhibitors and incubated on ice for 30 min by tapping every 10 min. The protein concentration was qualified using Coomassie Plus protein assay reagent (Thermo Scientific, Rockford, IL, USA). The quantitation of immunoblotting band intensity was carried out using ChemiDoc XRS + Molecular Imager software (Bio-Rad, Philadelphia, PA, USA).
Luciferase assay
HepG2 cells were first transfected with Dual-Luciferase construct harboring ISRE (pGL4.45) or IFNβ target sequence. After 8 h, the cells were then transfected with polyIC, polydAdT or pHBV1.3 plasmid; 16 h later, the cells were lysed with passive lysis buffer and the activity of Firefly Luciferase and Renilla Luciferase in the lysates were measured with the dualLuciferase Assay System (Promega, Madison, WI, USA).
Eenzyme-linked immunosorbent assay
Cells were mock-transfected or transfected with TRIM25 expression plasmid. After 48 h, cells were exposed to IFNα Type I IFN inhibits HBV by inducing IL-27 dependent TRIM25 G Tan et al (10 ng/ml) for 24 h. The supernatant was collected and subjected to enzyme-linked immunosorbent assay following the kit instructions (Kehua Shengwu, Shanghai, China).
CRISPR/Cas9 knockout
HepG2 or 293T cells were seeded in a 24-well plate; 16 h later, plasmids expressing Cas9 and TRIM25 or STAT1 or STAT3 single-guide RNA (sgRNA) and a plasmid with puromycin selection marker were co-transfected into cells using Viafect transfection reagent (Promega). At 36 h after transfection, cells were either selected by adding puromycin at a concentration of 2 μg/ml or subjected to immunoblotting with TRIM25-, IL27R1-,STAT1-or STAT3-specific antibodies (Cell Signaling). Two days later, living cells were diluted on a 96-well plate at 1 cell per well. Immunoblotting was performed again to ensure that the gene knockout (KO) results after the clones were formed. DNA sequencing was performed to further confirm the gene KO results. SgRNA for CRISPR KO are shown in Supplementary Table S1 .
Patient samples
Twenty-nine HBV-infected patients and 29 healthy subjects were enrolled in this study (Supplementary Table S2 ). Venous blood was withdrawn to prepare serum and PBMCs. These studies were approved by the institutional review board of Jilin University, The First Hospital.
Statistical analysis
The results were presented as the means ± s.d. and analyzed with Student's t-test. Po0.05 was considered statistically significant.
RESULTS

TRIM25 was upregulated by IFN treatment in both 293T and
HepG2 cells IFN antiviral function is achieved by inducing ISGs expression, which directly or indirectly inhibits different stages of the viral life cycle. 3 Many TRIM proteins are also ISGs and suppress viral replication. 24, 25 To investigate TRIM's response to IFN stimulation, we examined a group of TRIM gene messenger RNAs (mRNAs), including TRIM25 with Q-PCR in IFNα-treated HepG2 cells (Supplementary Figure S1 ). TRIM22 expression was the highest among a panel of TRIM genes including TRIM25 in response to IFN treatment. TRIM22 was reported to inhibit HBV replication by suppressing HBV core promoter activity, whereas TRIM25 was known to mediate the ubiquitination and activation of RIG-I, which is not only an RNA sensor but also functions as a virus sensor in HBV infection. 21, 26 Interestingly, TRIM25 mRNA was also significantly induced in 293T cells ( Figure 1a ). In addition, we performed western blot to detect the protein level. As expected, TRIM25 protein was elevated after IFNα treatment (Figures 1a  and b) . The reported TRIM25 antiviral response and elevated TRIM25 expression to IFN treatment prompted us to select TRIM25 for further investigation. Interestingly, the upregulation of TRIM25 by IFNα was significantly countered at the protein level when cycloheximide (CHX: a protein synthesis inhibitor that do not affect the mRNA synthesis) was added, and TRIM25 mRNA upregulation was also significantly inhibited, suggesting that IFN-induced protein expression was important in TRIM25 mRNA induction. However, CHX inhibition of TRIM25 induction appeared to wane when we treated the cells with supernatant from IFNα-stimulated HepG2 cells (Figures 1c and d) , which indicated that the supernatant may contain the secreted IFNα-induced cytokines that facilitated TRIM25 expression. Collectively, these results indicated that TRIM25 expression was significantly increased in cells to respond to IFN stimulation.
IL-27 was critical for TRIM25 induction Next, we investigated that cytokine was associated with TRIM25 induction. We previously studied the regulatory functions of IL-10 and IL-27, 7,27 and questioned if both cytokines are required. We found that both IL-10 basic expression and responsive induction were very low in HepG2 cells, whereas IL-27 was normally expressed and was elevated by IFN treatment (Figure 2a ), suggesting that IL-27 was a likely candidate. To test whether IL-27 is required for TRIM25 induction, we treated the cells with IL-27-neutralizing antibody and TRIM25 induction by IFN, which was blocked at both the mRNA and protein levels (Figures 2b and c) , indicating that IL-27 in the supernatant was important for TRIM25 induction by IFN. To further verify this relationship, IL27R was knocked out in 293T and HepG2 cells by the CRISPR/Cas9 system ( Figure 2d ). As expected, TRIM25 induction was blocked in both 293T and HepG2 IL27R KO cells (Figures 2e and f) . In addition, given that BMMs are responsive to type I IFN and are the main source of the type I IFN-inducible IL-27, 7,11 we tested TRIM25 induction in wild-type and IL27R1 −/− BMMs, and type I IFN-induced TRIM25 was also significantly inhibited in BMMs IL27R KO cells (Figure 2g) , suggested that the IFN-IL27-TRIM25 axis was not cell-specific. We further investigated whether IL27 could directly induce TRIM25 expression, as expected, both TRIM25 mRNA and protein level were upregulated by recombinant IL27 protein stimulation, and interestingly, both TRIM25 basal and induction level was significantly reduced in STAT1 or STAT3 KO 293T cells (Figures 2h and i) , which indicated that IFN-induced IL27 might elevate TRIM25 expression by activating STAT1 and STAT3. Collectively, all these data suggested that IL27 was critical for IFN-induced TRIM25 expression.
Both STAT1 and STAT3 were required for TRIM25 induction by IFN We further investigated the function of STAT1 and STAT3 in TRIM25 induction. As an ISG, we assumed that STAT1 is a major transcriptional factor in TRIM25 transcription; however, IL-27 was also reported to activate STAT3 via JAK-mediated phosphorylation in T cells 28 and liver cells; 29 consistently with previous reports, IL-27 protein promoted both IFN-induced STAT1 and STAT3 activation in HepG2 cells. The activation of STAT1 and STAT3 was inhibited by IL-27-neutralizing antibody upon IFN or IL-27 recombinant protein retreatment (Figures 3a-c) . STAT3 was activated in IFN-treated HepG2 cells at different time points (Supplementary Figure S2a) , and STAT3 activation was completely blocked by the STAT3-specific inhibitor Stattic (Supplementary Figure S2b) . In addition, type I IFN-induced TRIM25 expression was significantly inhibited by Stattic (Supplementary Figures S2c and d) . To confirm our result, we used the CRISPR KO technique to KO STAT1 and STAT3 in 293T cells. As expected, STAT1 KO blocked the induction of TRIM25 at the mRNA and protein levels, and STAT3 KO also inhibited TRIM25 mRNA and protein production (Figures 3d and e) . A similar pattern was observed in STAT3 KO HepG2 cells (Figures 3f and g ). Furthermore, small intefering RNA-mediated STAT3 knockdown in HepG2 cells also inhibited IFNα-induced TRIM25 production (Figure 3h ). The basal levels of TRIM25 in both 293T and HepG2 cells were reduced after STAT3 KO or knockdown. Taken together, both STAT1 and STAT3 were indispensable for the upregulation of TRIM25 in type I IFN treatment.
TRIM25 KO in HepG2 cells facilitated HBV replication
We found that the overexpression of TRIM25 with the HA tag inhibited HBeAg secretion and HBV DNA replication Figure S3a) . HBeAg and HBV DNA levels were significantly increased in TRIM25 KO HepG2 cells compared with WT cells, which suggested the inhibition of HBV replication by TRIM25 (Figures 4a and b) . We further investigated whether the overexpression of TRIM25 could inhibit HBV replication in HepG2.2.15 cells in which HBV keeps replicating. We found that HBeAg and HBsAg were significantly reduced in the supernatant of the overexpressed TRIM25 cells (Supplementary Figure S3b) . Interestingly, HBeAg in the supernatant of pHBV1.3-transfected TRIM25 KO HepG2 cells was increased after IFNα treatment, and HBV DNA in the (Figure 4b ). These data indicate that the upregulation of TRIM25 was an important mechanism for mediating anti-HBV response upon IFN treatment.
HBV replication increased in STAT3 KO cells
We previously showed that Apobec3G, an anti-HBV ISG, was STAT3-but not STAT1-dependent. 30 We questioned the biological impact of STAT3 on HBV replication. Consistent with our previous report, we found that HBV DNA, HBeAg and HBsAg were significantly increased after STAT3 KO in HepG2 cells, and that HBV replication was enhanced by IFNα treatment (Figure 5a ), indicating that STAT3 is required to inhibit HBV replication.
TRIM25 promoted type I IFN production in HepG2 cells
A previous report showed that IFNβ production was blocked in TRIM25 À / À MEFs. 21 To understand how TRIM25 inhibits HBV replication, we sought to determine whether TRIM25 increases IFN production. Notably, type I IFN was increased in TRIM25-overexpressed cells, and TRIM25 KO reduced the production of type I IFN in HepG2 cells (Figures 6a and b) . In addition, we questioned whether TRIM25 KO could reduce downstream ISG expression in liver cells. As expected, after transfection with polydAdT, polyIC or pHBV1.3 plasmids, an IFNβ or ISRE-Luc reporter assay indicated that luciferase activity induction was significantly inhibited in TRIM25 KO HepG2 cells (Figures 6c and d) , and the induction of ISGs by pHBV1.3 transfection was also significantly inhibited (Figure 6e ).
HBV infection inhibited TRIM25 expression
We next investigated whether HBV could inhibit TRIM25 expression in HBV patients. We found that TRIM25 expression in PBMCs isolated from HBV patients was significantly decreased compared with healthy controls (Figure 7a ). To confirm this finding in liver cells, we found that the addition of HBV serum could remarkably inhibit TRIM25 expression in HepG2 cells (Figure 7b ). In addition, the expression of TRIM25 in HepG2.2.15 cells in which HBV keeps replicating was significantly inhibited compared with HepG2 cells (Figure 7c ). The induction of TRIM25 by IFNα stimulation was inhibited after the HepG2 cells were co-cultured with HepG2.2.15 supernatants (Figure 7d ). HBV appears to resist IFN treatment by inhibiting TRIM25 expression.
DISCUSSION
In this study, we found: (1) IFN elevates TRIM25 expression via an IL-27-dependent regulatory loop, (2) both transcription factors STAT1 and STAT3 is required for the induction of TRIM25, (3) STAT3 is important for inhibiting HBV replication and (4) HBV infection/replication may inhibit TRIM25 expression. Our results provide a possible explanation for the poor response to IFN treatment in a portion of HBV-infected patients.
STAT3 is an important transcriptional factor in regulating ISGs expression and generally acts as a positive regulator. 31 For instance, the upregulation of CXCL11 (an IFN-inducible gene) by IFN was blocked in STAT3 KO cells. 8 However, STAT3 can also negatively regulate type I IFN -mediated antiviral response in MEFs. 32 For example, the expression of PKR, OAS and IRF1, which are well-characterized ISGs, was increased in STAT3 KO MEFs. Thus, the impact of STAT3 on ISGs can be bi-directional. As shown by Ho and Ivashkiv, 33 on the one hand, STAT3 downregulated the IFNα-mediated induction of inflammatory mediators such as the chemokines CXCL9 and CXCL10; on the other hand, IFNα-activated STAT3 supported the ISGF-3-dependent induction of antiviral genes.
Using CRISPR/Cas9 systems, we knocked out STAT1 and STAT3 in HepG2 cells. As expected, STAT1 KO blocked TRIM25 induction. Notably, TRIM25 upregulation was inhibited in STAT3-deficient HepG2 cells. Similarly, a treatment with a STAT3-specific inhibitor blocked the induction of TRIM25 by IFN stimulation. Collectively, both STAT1 and STAT3 are important for type I IFN -induced TRIM25 upregulation. In addition, our data show that HBV replication was not inhibited by IFN after STAT3 KO despite the continued expression of STAT1 in HepG2 cells. This suggested that STAT1 and STAT3 may function in tandem to deliver an antiviral response. 30 In response to RNA virus, TRIM25 E3 ubiquitin ligase induces the Lys 63-linked ubiquitination of RIG-I, which is a key component utilized by the cytosolic RIG-I signaling pathway in mounting host antiviral innate immunity. 21 RIG-I, an RNA sensor, could also act as an innate sensor and antiviral factor for HBV by counteracting HBV polymerase (P protein). 26 In HIV infection, TRIM5α, another member of the TRIM family, can interact with incoming HIV capsid and send it for hydrolysis through the ubiquitin pathway. It would be interesting to investigate whether TRIM25 can exert direct anti-HBV activity. In this study, we showed that type I IFN was significantly reduced in TRIM25 KO HepG2 cells and that the overexpression of TRIM25 in HepG2 cells promoted IFN production. These data indicate that TRIM25 may also inhibit HBV replication by boosting type I IFN signaling and thereby further amplifying downstream anti-HBV ISGs production.
Unexpectedly, TRIM25 expression was significantly inhibited in PBMCs isolated from HBV-infected patients, and the addition of HBV patient serum inhibited TRIM25 expression in HepG2 cells. Our results suggest that HBV life cycle might utilize a mechanism inhibiting ISG expression. This finding was consistent with a previous report showing that HBV can suppress the TLR-induced antiviral activity in liver cells. 34 Major vault protein (MVP) is a novel virus-induced host factor that upregulates type I IFN production. A recent report showed that HBV inhibited the MVP-and MyD88-induced activation of NF-κB and IFN-β by disrupting MVP/MyD88 interactions. 35 In this study, IFNα was not reduced in the PBMCs of HBV patients; the TRIM25 reduction in HBV patients may show that HBV products inhibit the activation of some transcriptional factors including STAT1 and STAT3. Notably, both STAT1 and STAT3 were required for IFN -induced TRIM25 upregulation; thus, it is conceivable that HBV may inhibit TRIM25 by suppressing STAT1 and STAT3 activation. This understanding is consistent with our earlier study showing that HBVs could inhibit STAT3-S727 phosphorylation and further reduce APOBEC3G induction by IFN in HepG2 cells. 30 Based on these findings, we propose a working model for TRIM25 in mediating the crosstalk between type I IFN and HBV infection (Figure 8 ). In conclusion, we found that the type I IFNs induced IL-27, which activated STAT1 and STAT3 to promote TRIM25 gene expression. The elevated 
